BRPI0710959B8 - uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular. - Google Patents

uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.

Info

Publication number
BRPI0710959B8
BRPI0710959B8 BRPI0710959A BRPI0710959A BRPI0710959B8 BR PI0710959 B8 BRPI0710959 B8 BR PI0710959B8 BR PI0710959 A BRPI0710959 A BR PI0710959A BR PI0710959 A BRPI0710959 A BR PI0710959A BR PI0710959 B8 BRPI0710959 B8 BR PI0710959B8
Authority
BR
Brazil
Prior art keywords
prevention
treatment
secretory
fragments
manufacture
Prior art date
Application number
BRPI0710959A
Other languages
English (en)
Portuguese (pt)
Inventor
Jennische Eva
Hansson Hans-Arne
Lange Stefan
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of BRPI0710959A2 publication Critical patent/BRPI0710959A2/pt
Publication of BRPI0710959B1 publication Critical patent/BRPI0710959B1/pt
Publication of BRPI0710959B8 publication Critical patent/BRPI0710959B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0710959A 2006-04-27 2007-04-27 uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular. BRPI0710959B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600932-8 2006-04-27
SE0600932 2006-04-27
PCT/SE2007/000414 WO2007126364A2 (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Publications (3)

Publication Number Publication Date
BRPI0710959A2 BRPI0710959A2 (pt) 2012-02-28
BRPI0710959B1 BRPI0710959B1 (pt) 2018-11-06
BRPI0710959B8 true BRPI0710959B8 (pt) 2021-05-25

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710959A BRPI0710959B8 (pt) 2006-04-27 2007-04-27 uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.

Country Status (18)

Country Link
US (2) US8207296B2 (enExample)
EP (2) EP2015767B1 (enExample)
JP (2) JP5284948B2 (enExample)
KR (1) KR20090040404A (enExample)
CN (2) CN101432013B (enExample)
AU (1) AU2007244004B2 (enExample)
BR (1) BRPI0710959B8 (enExample)
CA (2) CA2771087C (enExample)
DK (2) DK2015767T3 (enExample)
ES (2) ES2773945T3 (enExample)
IL (1) IL194773A (enExample)
MX (1) MX2008013769A (enExample)
NZ (2) NZ572255A (enExample)
PL (2) PL2015767T3 (enExample)
RU (1) RU2458703C2 (enExample)
SG (1) SG171602A1 (enExample)
WO (1) WO2007126364A2 (enExample)
ZA (1) ZA200809115B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2458703C2 (ru) * 2006-04-27 2012-08-20 Лантменнен Ас-Фактор Новый подход к лечению повышенного внутриглазного давления
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
EP2396024A4 (en) * 2009-02-11 2013-02-27 Lantmaennen As Faktor Ab USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
WO2014096384A1 (en) * 2012-12-20 2014-06-26 Lantmännen As-Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
ES2887086T3 (es) * 2015-07-10 2021-12-21 Lantmaennen Functional Foods Ab Procedimiento para producir yema de huevo con alto contenido de af-16
KR102268955B1 (ko) 2016-07-18 2021-06-25 란트만넨 아스-팍토르 아베 항분비 인자 17
US20250177480A1 (en) 2018-06-28 2025-06-05 Lantmännen Medical Ab Antisecretory Factor for Use in Treatment and/or Prevention of Acute Respiratory Failure
EP3855935A1 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted wheat
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
AU2021243735A1 (en) 2020-03-26 2022-10-13 Lantmännen Functional Foods Ab A consumable product comprising malted cereals for promoting recovery at physical activity
WO2024102346A1 (en) * 2022-11-08 2024-05-16 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
CN1335887A (zh) * 1999-06-21 2002-02-13 印坎药物股份有限公司 血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
MX2008013777A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
DK2037950T3 (da) * 2006-04-27 2014-06-30 Lantmännen As Faktor Ab Yderligere medicinske anvendelser af antisekretorisk protein
RU2458703C2 (ru) * 2006-04-27 2012-08-20 Лантменнен Ас-Фактор Новый подход к лечению повышенного внутриглазного давления

Also Published As

Publication number Publication date
DK2468292T3 (da) 2020-03-23
BRPI0710959A2 (pt) 2012-02-28
JP2009535329A (ja) 2009-10-01
MX2008013769A (es) 2009-02-03
US8207296B2 (en) 2012-06-26
ES2561945T3 (es) 2016-03-01
CN101432013B (zh) 2015-01-07
CA2650344C (en) 2017-10-31
IL194773A (en) 2015-07-30
BRPI0710959B1 (pt) 2018-11-06
US20090162296A1 (en) 2009-06-25
AU2007244004B2 (en) 2012-02-09
EP2015767B1 (en) 2016-01-06
EP2468292B8 (en) 2020-02-26
JP2012153695A (ja) 2012-08-16
KR20090040404A (ko) 2009-04-24
JP5284948B2 (ja) 2013-09-11
ES2773945T3 (es) 2020-07-15
ZA200809115B (en) 2009-07-29
US9000125B2 (en) 2015-04-07
EP2468292A1 (en) 2012-06-27
CN102633863B (zh) 2014-08-06
CA2650344A1 (en) 2007-11-08
WO2007126364A3 (en) 2008-03-06
CA2771087C (en) 2016-03-15
CA2771087A1 (en) 2007-11-08
DK2015767T3 (en) 2016-02-08
EP2468292B1 (en) 2019-12-18
EP2015767A2 (en) 2009-01-21
WO2007126364A8 (en) 2009-07-23
SG171602A1 (en) 2011-06-29
CN101432013A (zh) 2009-05-13
AU2007244004A1 (en) 2007-11-08
NZ598426A (en) 2012-08-31
RU2458703C2 (ru) 2012-08-20
CN102633863A (zh) 2012-08-15
US20120283191A1 (en) 2012-11-08
NZ572255A (en) 2012-03-30
PL2015767T3 (pl) 2016-05-31
WO2007126364A2 (en) 2007-11-08
IL194773A0 (en) 2011-08-01
PL2468292T3 (pl) 2020-08-24
RU2008146733A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
BRPI0710959B8 (pt) uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
MX2009007065A (es) Variantes de desintegrina y usos farmaceuticos de los mismos.
CR9807A (es) Uso de derivados de azabiciclohexano
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BRPI0708802A2 (pt) inserto corneal intra-estromal pré-formado para anormalidades ou distrofias corneais
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
BRPI0519355A2 (pt) compostos para tratamento contra flaviviridae
IL267555A (en) Ostraulicin, a functionally related variette, an extract containing ostraulicin and its uses
EP2106260A4 (en) INSULIN SENSITIZERS AND TREATMENT PROCEDURES THEREWITH
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2004087734A3 (en) Stq-peptides
CN110891597A (zh) 防治家禽滑膜霉浆菌感染的组合物
CA3168457C (en) PHILLYRINE TARGETING 3 CLPRO, ITS DERIVATIVE AND ITS USE AGAINST THE NOVEL CORONAVIRUS
WO2006074452A3 (en) Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
BR112022019403A2 (pt) Uso de um derivado de tienopiridona no tratamento de doença renal policística autossômica dominante (drpad)
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.